Oxymorphone Extended Release

DRUG4 trials

Sponsors

Endo Pharmaceuticals

Conditions

CancerChronic DiseaseChronic PainNeuropathic PainPain

Phase 3

Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

CompletedNCT00225797

Endo PharmaceuticalsChronic Pain

Start: 2004-11-30End: 2005-07-31Target: 160Updated: 2024-01-02

Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain

CompletedNCT00226421

Endo PharmaceuticalsChronic Pain

Start: 2004-10-31End: 2005-08-31Target: 120Updated: 2024-01-02

Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain

CompletedNCT00911261

Endo PharmaceuticalsCancer, Chronic Pain, Neuropathic Pain

Start: 2003-08-31End: 2005-05-31Updated: 2010-02-15

Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain

CompletedNCT00911287

Endo PharmaceuticalsChronic Disease, Pain

Start: 2003-06-30End: 2004-03-31Updated: 2010-02-10

Related Papers

Tolerability of concomitant use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release.

2012-03-013 citations

Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis.

2010-08-015 citations